Ropivacaine 0.2% Injectable Solution

Preclinical

Ropivacaine 0.2% Injectable Solution is one of 5 therapeutic programs targeting Hip Osteoarthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hip OsteoarthritisRecruiting

Knee OsteoarthritisNot yet recruiting

Hip OsteoarthritisPreclinical

Recruiting

Knee OsteoarthritisPreclinical

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Knee Osteoarthritis

#DrugCompanyPhaseTrials

Inulin and Sodium Chloride

BBlue Earth Diagnostics

Phase 2

1 2

Maltodextrin

RRDC Clinical Pty Ltd

Phase 2

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

Decadron

AAspen Global Incorporated

Preclinical

1 5

Ropivacaine 0.2% Injectable Solution

PPoznan University of Medical Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

PreclinicalRecruiting

Hip Osteoarthritis

NCT07449403

Q4 2027

PreclinicalNot yet recruiting

Knee Osteoarthritis

NCT07677215

Clinical

Trials by Indication[1]

Hip Osteoarthritis1 trial

Pericapsular Nerve Group Block Mitigates Surgical Stress and Enhances Analgesia in Total Hip Arthroplasty: A Randomized Controlled Trial

Recruiting·PPoznan University of Medical Sciences·Preclinical·NCT07449403·60 enrolled

Knee Osteoarthritis1 trial

Comparison of the Efficacy and Safety of Three Adjuvant Strategies for ACB and iPACK Blocks in Patients Undergoing Elective Total Knee Arthroplasty: A Prospective, Randomized Clinical Trial

Not yet recruiting·PPoznan University of Medical Sciences·Preclinical·NCT07677215·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ropivacaine 0.2% Injectable Solution. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ropivacaine 0.2% Injectable Solution. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Poznan University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: PPoznan University of Medical Sciences

Ropivacaine 0.2% Injectable Solution

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Trials by Indication[1]

Hip Osteoarthritis1 trial

Knee Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News